Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05436990 | Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor | terminated | Phase 2 | 14 | Yonsei UniversityOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT05695898 | XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy | terminated | Phase 1 | 6 | University of California, San FranciscoOTHER | 1 | Mar 26, 2025 |
| clinicaltrials |
| NCT04990479 | Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma | terminated | Phase 1 | 7 | Nouscom SRLINDUSTRY | 3 | Mar 20, 2025 | clinicaltrials |
| NCT04629339 | Study of INCB086550 in Select Solid Tumors | terminated | Phase 2 | 16 | Incyte CorporationINDUSTRY | 5 | Mar 13, 2025 | clinicaltrials |
| NCT04032704 | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | terminated | Phase 2 | 205 | Seagen Inc.INDUSTRY | 6 | Mar 10, 2025 | clinicaltrials |
| NCT05576077 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors(STARLING) | terminated | Phase 1 | 31 | Turnstone Biologics, Corp.INDUSTRY | 2 | Mar 10, 2025 | clinicaltrials |
| NCT03997474 | ATL001 in Patients With Metastatic or Recurrent Melanoma | terminated | Phase 1 / Phase 2 | 13 | Achilles Therapeutics UK LimitedINDUSTRY | 2 | Mar 7, 2025 | clinicaltrials |
| NCT04901988 | Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION(DETECTION) | terminated | Phase 2 / Phase 3 | 8 | The Christie NHS Foundation TrustOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT05909995 | Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors | terminated | Phase 1 | 8 | Incyte CorporationINDUSTRY | 3 | Feb 18, 2025 | clinicaltrials |
| NCT00560118 | Fotemustine in Treating Patients With Metastatic Melanoma(MGFOT1) | terminated | Phase 2 | 12 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | terminated | Phase 1 | 133 | Seagen Inc.INDUSTRY | 6 | Feb 10, 2025 | clinicaltrials |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | terminated | Phase 1 / Phase 2 | 15 | Aminex Therapeutics, Inc.INDUSTRY | 2 | Dec 24, 2024 | clinicaltrials |
| NCT04967196 | Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma | terminated | Phase 1 | 6 | Mayo ClinicOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT03950635 | Dietary Intervention in Patients with a History of Melanoma | terminated | Phase 1 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT04375527 | Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma | terminated | Phase 2 | 3 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT05744128 | CD8 Minibody Repeatability Study(PRETZCEL) | terminated | Phase 2 | 3 | ImaginAb, Inc.INDUSTRY | 1 | Dec 3, 2024 | clinicaltrials |
| NCT05457842 | A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery | terminated | Phase 2 | 1 | Astellas Pharma IncINDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT01217411 | RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06448364 | A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination(LTbR) | terminated | Phase 1 | 4 | PfizerINDUSTRY | 2 | Nov 6, 2024 | clinicaltrials |
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | terminated | Phase 1 | 15 | Molecular Templates, Inc.INDUSTRY | 1 | Nov 1, 2024 | clinicaltrials |
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer(PDL1x41BB) | terminated | Phase 1 | 160 | Inhibrx Biosciences, IncINDUSTRY | 1 | Oct 23, 2024 | clinicaltrials |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | terminated | Phase 2 | 40 | Rain Oncology IncINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT02097225 | Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | terminated | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Oct 16, 2024 | clinicaltrials |
| NCT03207867 | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | terminated | Phase 2 | 315 | Novartis PharmaceuticalsINDUSTRY | 15 | Oct 9, 2024 | clinicaltrials |
| NCT00863330 | Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma | terminated | Phase 2 | 14 | Wake Forest University Health SciencesOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT03476174 | Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma | terminated | Phase 2 | 1 | Ralph HaukeOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT03712358 | PVSRIPO for Patients With Unresectable Melanoma | terminated | Phase 1 | 12 | Istari Oncology, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05200143 | Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma | terminated | Phase 2 | 4 | Providence Health & ServicesOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03370861 | How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes(MINING) | terminated | — | 54 | Washington University School of MedicineOTHER | 1 | Sep 5, 2024 | clinicaltrials |
| NCT04768881 | Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma | terminated | Phase 2 | 15 | Karyopharm Therapeutics IncINDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT03233828 | Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2(IL-2) | terminated | Phase 3 | 1 | Carman GiacomantonioOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT03978611 | A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment | terminated | Phase 1 | 11 | Bristol-Myers SquibbINDUSTRY | 6 | Jul 24, 2024 | clinicaltrials |
| NCT04198818 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors | terminated | Phase 1 / Phase 2 | 37 | Haihe Biopharma Co., Ltd.INDUSTRY | 2 | Jul 19, 2024 | clinicaltrials |
| NCT04924413 | L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma | terminated | Phase 2 | 9 | Quanli GaoOTHER_GOV | 1 | Jul 3, 2024 | clinicaltrials |
| NCT03685591 | PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 49 | PfizerINDUSTRY | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03621982 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | terminated | Phase 1 | 78 | ADC Therapeutics S.A.INDUSTRY | 3 | Jun 13, 2024 | clinicaltrials |
| NCT04655157 | Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma(QUAD01) | terminated | Phase 1 / Phase 2 | 2 | Jason J. Luke, MDOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT03893019 | MB-CART20.1 Melanoma | terminated | Early Phase 1 | 9 | Miltenyi Biomedicine GmbHINDUSTRY | 1 | May 16, 2024 | clinicaltrials |
| NCT02621515 | Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases(CA209-322) | terminated | Phase 2 | 7 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT02700763 | [18F]Dabrafenib Molecular Imaging in Melanoma Brain Metastasis | terminated | N/A | 1 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT02922283 | IL2 Imaging in Metastatic Melanoma | terminated | N/A | 19 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT00199342 | A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma | terminated | Phase 1 / Phase 2 | 5 | Kyowa Kirin, Inc.INDUSTRY | 1 | May 3, 2024 | clinicaltrials |
| NCT04879017 | FHD-286 in Subjects With Metastatic Uveal Melanoma | terminated | Phase 1 | 76 | Foghorn Therapeutics Inc.INDUSTRY | 3 | Apr 25, 2024 | clinicaltrials |
| NCT05709821 | IMM60 and Pembrolizumab in Melanoma and NSCLC | terminated | Phase 1 / Phase 2 | 1 | iOx TherapeuticsINDUSTRY | 3 | Apr 24, 2024 | clinicaltrials |
| NCT05050006 | ITIL-168 in Advanced Melanoma(DELTA-1) | terminated | Phase 2 | 29 | Instil BioINDUSTRY | 3 | Apr 16, 2024 | clinicaltrials |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | terminated | Phase 1 | 13 | PfizerINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT02978443 | A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab | terminated | Phase 2 | 14 | Georgetown UniversityOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT03727789 | CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma | terminated | Phase 1 | 7 | Roswell Park Cancer InstituteOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT04899921 | Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets | terminated | Phase 2 | 1 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT02723006 | Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma | terminated | Phase 1 | 22 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 5, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Apr 2, 2025source: clinicaltrials